10:23 AM
 | 
Sep 28, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best overall response rate (ORR) of 30%. All three responders achieved partial responses, plus four patients achieved stable disease and three patients had...

Read the full 265 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >